Noncovalent Bruton tyrosine kinase (BTK) inhibitor pirtobrutinib and chimeric antigen receptor (CAR) T-cell therapy lisocabtagene maraleucel have gained FDA approval for double-refractory chronic ...
Panelists discuss how emerging therapies like menin inhibitors show promise based on strong preclinical data and clinical responses, while CD47 inhibitors have faced setbacks in phase 3 trials, with ...
Moltbook is a ‘social network for agents’. It launched last week and by this morning had 1.5 million agents onboard, many of which are engaging with others. It’s been framed by some as a ...
Please provide your email address to receive an email when new articles are posted on . Researchers reported an encouraging pathologic complete response rate with SHR-A1811 monotherapy. No ...
Please provide your email address to receive an email when new articles are posted on . ORLANDO — In this video, Stephen M. Ansell, MD, PhD, discusses highlights in rare histologies, including ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results